Generic medicines developer Renova Pharmaceuticals LLC announced on Thursday the commercial launch of its first three FDA-approved generic products in the United States: L-Glutamine for Oral Solution, Dimethyl Sulfoxide (DMSO) Irrigation, 50%, and Ascorbic Acid Injection.

These launches mark Renova's transition from building its development and regulatory pipeline to establishing a growing commercial presence in the US generics market.

Renova's Dimethyl Sulfoxide (DMSO) Irrigation, 50% received FDA approval with Competitive Generic Therapy (CGT) designation.

Renova is building a diversified portfolio across sterile injectables, ophthalmics, complex generics and select oral dosage forms, with additional products progressing through development and FDA review.